Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06988462 · ClinicalTrials.gov registry record · NA
Pilot Study of "Bottarga" Supplementation: A Little-known, Sustainable "Blue" Food
A NA study of Diabetes and PreDiabetes, sponsored by Cambridge Health Alliance.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06988462 is a NA study of Diabetes and PreDiabetes that is actively recruiting participants, run by Cambridge Health Alliance. The registered enrollment target is 20 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06988462, a NA study of Diabetes and PreDiabetes, is actively recruiting participants, sponsored by Cambridge Health Alliance.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot study aims to explore the potential benefits of consuming Greek bottarga (grey mullet fish roe) in individuals with at least one metabolic abnormality (low HDL cholesterol, high LDL cholesterol, high triglycerides, obesity, or HbA1c ≥ 5.7%) or a diagnosis of diabetes. Before initiating the crossover randomized controlled trial (RCT), the investigators will conduct a preliminary dose-testing study in five adults with at least one metabolic abnormality. Participants will undergo clinical assessments before and after the dietary intervention to evaluate changes in metabolic health markers. Following this phase, the investigators will proceed with a randomized, controlled crossover trial involving 20 eligible adult participants. This main study phase will compare the metabolic effects of daily bottarga supplementation with those of a calorically matched dairy product over an 8-week intervention period, with a 2-week washout period between interventions. The investigators anticipate that bottarga supplementation will improve lipid profiles, inflammation markers, and insulin resistance, thereby supporting the potential use of sustainable blue foods as part of a healthy diet.
Conditions Studied
Interventions
- OTHER Bottarga
- OTHER Comparator
Study Locations (1)
Massachusetts
- Cambridge Health Alliance - Sommerville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-10-17 |
| Est. Completion | 2026-12-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06988462
The ClinicalTrials.gov registry entry for NCT06988462 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The listed sponsor is Cambridge Health Alliance, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Bottarga is the first listed.
NCT06988462 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06988462 about?
NCT06988462 is a clinical study titled "Pilot Study of "Bottarga" Supplementation: A Little-known, Sustainable "Blue" Food". This pilot study aims to explore the potential benefits of consuming Greek bottarga (grey mullet fish roe) in individuals with at least one metabolic abnormality (low HDL cholesterol, high LDL cholesterol, high triglycerides, obesity, or HbA1c ≥ 5.7%) or a diagnosis of diabetes. Before initiating t...
What is the current status of trial NCT06988462?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2025-10-17. Estimated completion is 2026-12-01.
What conditions does trial NCT06988462 study?
This clinical trial studies the following conditions: Diabetes, PreDiabetes, Obesity & Overweight, Triglycerides, High Cholesterol/Hyperlipidemia.
What interventions are being tested in trial NCT06988462?
The interventions under investigation include: Bottarga (OTHER), Comparator (OTHER).
Who is sponsoring clinical trial NCT06988462?
This trial is sponsored by Cambridge Health Alliance, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06988462 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge
RECRUITING · NA
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c
RECRUITING · NA
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
-
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
RECRUITING · NA
-
Bringing Advocacy Via Digital Guide to the Emergency Department (Project BADGE)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.